To compare rate of switching among biologic naive Psoriatic Arthritis patients initiating apremilast or biologics- Results from a Us Claims Database
Latest Information Update: 21 Jun 2019
At a glance
- Drugs Apremilast (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Ixekizumab; Secukinumab; Ustekinumab
- Indications Psoriatic arthritis
- Focus Therapeutic Use
Most Recent Events
- 15 Jun 2019 Results comparing the rate of treatment switching among adult patients initiating treatment with apremilast, TNF inhibitor or IL inhibitors, presented at the 20th Annual Congress of the European League Against Rheumatism.
- 24 May 2019 New trial record
- 22 May 2019 Results presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research